In the autumn of 1974, a first-year medical student at UCLA named Kay Redfield Jamison began to experience something that she would later describe as "a great tidal wave of energy." It began as a pleasant sensation — a heightened sense of purpose, a feeling that her mind was moving faster and more brilliantly than it ever had. She worked all night without effort. Ideas cascaded. The world seemed extraordinarily vivid. She bought plants, dozens of them, then more clothes than she could possibly wear, then more books than she could read in a decade. The expenditure escalated until she was spending far beyond her means, but the logic felt impeccable in the moment — she was going to need all of these things for the plans she was making. The plans were vast, detailed, and entirely rational to her. To others, they were the plans of someone in crisis.
Within months, what had begun as elation had curdled into something else: a darkness so profound that Jamison found herself on the floor of her apartment, unable to move, convinced she was worthless and that death was the only sensible conclusion. She would eventually be hospitalized, receive a diagnosis of manic-depressive illness — the term then in use for what is now called bipolar I disorder — and begin what would become a decades-long negotiation between the demands of her illness, the requirements of her treatment (particularly lithium, which she resisted fiercely for years), and her career as a clinical psychologist and researcher. She eventually became one of the world's leading scientists on mood disorders, with a particular expertise in the very condition she had been living with.
Her 1995 memoir, "An Unquiet Mind," describes her first manic episode with the precision of a clinician and the candor of a patient: "There is a particular kind of pain, elation, loneliness, and terror involved in this kind of madness. When you're high it's tremendous. The ideas and feelings are fast and frequent like shooting stars, and you follow them until you find better and brighter ones. Shyness goes, the right words and gestures are suddenly there, the power to captivate others a felt certainty." This portrait of what bipolar disorder actually feels like from the inside — not merely as a list of diagnostic criteria but as a lived experience with its own terrifying logic — transformed how both the public and many clinicians thought about the condition.
"There is a particular kind of pain, elation, loneliness, and terror involved in this kind of madness. When you're high it's tremendous. The ideas and feelings are fast and frequent like shooting stars, and you follow them until you find better and brighter ones." — Kay Redfield Jamison, An Unquiet Mind (1995)
Key Definitions
Bipolar disorder: a class of mood disorders characterized by episodes of mania or hypomania (abnormally elevated, expansive, or irritable mood) and, in most cases, episodes of depression.
Mania: a distinct period of abnormally and persistently elevated, expansive, or irritable mood lasting at least seven days (or any duration if hospitalization is required), accompanied by increased energy and at least three of the following: grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased goal-directed activity, and excessive involvement in risky activities.
| Feature | Bipolar I | Bipolar II | Cyclothymia |
|---|---|---|---|
| Manic episodes | Full mania (often requiring hospitalization) | No full mania | Hypomanic symptoms only |
| Depressive episodes | Present | Prominent — more time in depression | Mild depressive symptoms |
| Severity | Most severe form | Significant impairment, especially during depression | Milder, chronic mood instability |
| Lifetime prevalence | ~1% | ~1-2% | ~0.4-1% |
Hypomania: a less severe form of mania, lasting at least four days, that does not cause marked functional impairment or require hospitalization, and does not include psychotic features.
Bipolar I disorder: the most severe form, defined by the presence of at least one full manic episode.
Bipolar II disorder: defined by at least one hypomanic episode and at least one major depressive episode, with no history of full mania.
Cyclothymic disorder: a chronic pattern of hypomanic symptoms alternating with depressive symptoms over at least two years, without meeting full criteria for either.
Mixed features: the simultaneous presence of both manic/hypomanic and depressive symptoms.
Rapid cycling: four or more mood episodes (of any type) within a twelve-month period; associated with worse prognosis.
Kindling hypothesis: the theory that early mood episodes sensitize the brain such that subsequent episodes are triggered by progressively smaller environmental stressors.
Lithium: a naturally occurring element (alkali metal) that is the gold-standard mood stabilizer for bipolar disorder, with the strongest evidence base of any mood stabilizer for both acute mania and long-term maintenance.
Social zeitgeber theory: the theory that disruptions to social rhythms — routines governing sleep, mealtimes, and social engagement — trigger mood episodes in genetically vulnerable individuals by dysregulating circadian rhythms.
IPSRT: Interpersonal and Social Rhythm Therapy, a psychotherapy specifically developed for bipolar disorder targeting both circadian rhythm regulation and interpersonal functioning.
Diagnostic Classification: The DSM-5 Spectrum
Bipolar disorder is not a single condition but a spectrum of related mood disorders defined by the presence, severity, and duration of manic and hypomanic episodes. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5, 2013) defines four primary diagnostic categories within the bipolar spectrum.
Bipolar I disorder is the most severe category and requires at least one full manic episode. The manic episode must last at least seven days (or be severe enough to require hospitalization), must represent a distinct change from usual behavior, and must cause marked impairment in social or occupational functioning or include psychotic features. Depression is common in bipolar I — the vast majority of patients experience depressive episodes — but is not required for the diagnosis. Psychosis (delusions and hallucinations) occurs in approximately 50% of manic episodes, making bipolar I among the psychiatric conditions most associated with psychotic features.
Bipolar II disorder requires at least one hypomanic episode and at least one major depressive episode, with no history of full mania. This distinction matters clinically: bipolar II patients are frequently misdiagnosed with unipolar depression because they commonly seek treatment during depressive episodes and may not identify or report their hypomanic periods, which they may experience as pleasant or productive. The depressive episodes in bipolar II are often longer and more severe than in bipolar I, and bipolar II carries a high risk of suicide.
Cyclothymic disorder involves a chronic, fluctuating mood pattern with numerous periods of hypomanic symptoms and depressive symptoms over at least two years, without meeting full criteria for hypomanic or major depressive episodes. Although it is formally a milder category, cyclothymia causes significant impairment and carries a risk of progression to bipolar I or II.
Prevalence estimates vary with diagnostic criteria. Bipolar I affects approximately 1% of the general population; bipolar II approximately 1.1%; cyclothymia approximately 0.4-1%. When subsyndromal presentations are counted within a "bipolar spectrum," prevalence estimates reach 2-4%.
Distinguishing Bipolar from Unipolar Depression
One of the most clinically consequential diagnostic distinctions in psychiatry is between bipolar disorder and unipolar major depressive disorder. The two conditions share the depressive pole, and patients with bipolar II or cyclothymia commonly present for treatment during depressive episodes without spontaneously disclosing hypomanic periods — either because they do not recognize them as pathological, because they experienced them as pleasant, or because they occurred years earlier.
The consequences of misdiagnosis are significant. Antidepressant monotherapy — standard treatment for unipolar depression — carries a risk of inducing mania or hypomania, accelerating mood cycling, or inducing mixed states in patients with undiagnosed bipolar disorder. Clinical features that should raise suspicion of a bipolar diagnosis in a depressed patient include early age of onset, atypical depressive features (hypersomnia, hyperphagia, mood reactivity), a family history of bipolar disorder, brief antidepressant response followed by relapse, and any history of elevated energy or decreased sleep need associated with unusual productivity or risk-taking behavior.
The Phenomenology of Mania
Mania is one of the most distinctive psychiatric experiences — a state so far from ordinary that people who have not experienced it often find it difficult to understand, and people who have experienced it often struggle to convey what made it so compelling and so devastating.
The classical manic state involves several simultaneous alterations. Sleep need is dramatically reduced — a manic patient may sleep two or three hours and feel more energetic than after eight hours of normal sleep. Speech is pressured and accelerated, difficult to interrupt, leaping rapidly from topic to topic. Thought is experienced as racing: ideas arrive faster than they can be expressed. Self-assessment is radically inflated: the manic patient feels unusually talented, attractive, and important, with plans for achievements that seem entirely achievable. Perceptual experience is often heightened: colors appear brighter, music more beautiful, the world more vivid.
These features are not simply unpleasant — many patients describe their manic episodes, at least early on, as the most alive they have ever felt. Jamison's description of "shooting stars" captures this: the sense of mental abundance, of ideas proliferating faster than they can be captured. This experiential richness is part of why bipolar disorder is associated with treatment resistance and medication non-adherence: patients who have experienced the exhilaration of early mania often resist treatments that prevent it, even knowing the consequences.
The consequences are severe. As mania progresses, judgment deteriorates. The grandiosity that felt like confidence becomes recklessness — financial, sexual, professional. Impulsive decisions made during manic episodes — large financial transactions, sexual encounters outside of committed relationships, quitting jobs, confrontations with authority — can permanently alter the course of a patient's life. Psychosis, when it occurs, can involve elaborate delusional systems or command hallucinations. Hospitalization is often required to protect the patient from the consequences of their own judgment.
Hypomanic States
Hypomania presents the same features as mania but at lower intensity and without causing the marked functional impairment, psychosis, or need for hospitalization that characterize full manic episodes. Many patients experience hypomanic periods as genuine advantages: heightened energy, reduced need for sleep, increased productivity, social facility, and elevated confidence without the reckless excess of full mania. This is why bipolar II is sometimes referred to as the "successful" form of bipolar disorder — its hypomanic periods can be compatible with high achievement.
This phenomenology makes bipolar II genuinely difficult to diagnose. Patients in hypomanic states often see no reason to seek treatment. They feel good. Their productivity may genuinely be elevated. Only in retrospect, or from the vantage point of depression, does the hypomania appear as part of a cycle rather than as a fortunate period of high function.
The Neuroscience and Genetics of Bipolar Disorder
Bipolar disorder is among the most heritable of all psychiatric conditions. Twin studies consistently find concordance rates of approximately 40-70% in monozygotic (identical) twins compared to 5-10% in dizygotic (fraternal) twins, yielding heritability estimates of around 80-85%. First-degree relatives of individuals with bipolar disorder have approximately a seven-fold elevated lifetime risk of developing the condition.
Genetic Architecture
Genome-wide association studies (GWAS) have identified dozens of genetic risk loci for bipolar disorder, with the largest studies finding significant associations at genes involved in calcium signaling (particularly CACNA1C, encoding a voltage-gated calcium channel subunit), glutamate transmission, and circadian rhythm regulation. The genetic architecture resembles other complex traits: many common genetic variants of small individual effect contribute to overall risk, with no single gene accounting for more than a small fraction of heritability.
Crucially, bipolar disorder shares a substantial proportion of common risk variants with schizophrenia — the two conditions have a genetic correlation of approximately 0.7, meaning that most genetic variants that increase risk for one also increase risk for the other. This genetic overlap is consistent with the clinical overlap between the conditions, particularly in the psychotic features of bipolar I, and suggests that the categorical distinction between bipolar disorder and schizophrenia in DSM may not fully capture the underlying biological reality.
Neurobiological Mechanisms
Several neurobiological mechanisms have been investigated in bipolar disorder. Circadian rhythm dysregulation is among the most robust and theoretically important findings. The social zeitgeber theory, developed by Ellen Frank and Stacey Hlastala at the University of Pittsburgh, proposes that disruptions to social routines — regular sleep schedules, mealtimes, and social engagements — serve as environmental triggers for mood episodes in genetically vulnerable individuals by disrupting the circadian clock. Sleep deprivation is a well-established manic trigger, and the regularity of daily routines is a significant predictor of mood stability in prospective studies of bipolar patients.
At the neurochemical level, dopaminergic dysregulation is implicated in the mania pole: dopamine agonists (drugs that increase dopamine activity) can induce manic-like states, and post-mortem and neuroimaging studies suggest elevated dopamine sensitivity in patients who have experienced mania. Glutamatergic dysregulation appears important for both poles. Structural neuroimaging studies have found reductions in prefrontal cortex volume in bipolar patients, consistent with impaired top-down regulatory control over limbic structures including the amygdala — a finding that parallels the cognitive impairments in executive function and emotion regulation that characterize the interepisode period.
The kindling hypothesis, associated with psychiatrist Frank Post, proposes that early mood episodes sensitize neural circuits such that subsequent episodes are triggered by progressively smaller environmental stressors — an analogy to the kindling of seizure activity in epilepsy. This model is consistent with the clinical observation that episode frequency often increases over the course of illness, and that anticonvulsant medications effective for epilepsy (valproate, lamotrigine, carbamazepine) are also effective mood stabilizers.
Treatment: Lithium and Beyond
Treatment for bipolar disorder requires a lifespan approach addressing multiple phases of illness: acute mania, acute bipolar depression, and long-term maintenance. No single medication is equally effective across all phases, and treatment planning requires careful balancing of benefits and side effects.
Lithium: History and Mechanism
Lithium's entry into psychiatry is one of the most serendipitous stories in the history of medicine. Australian psychiatrist John Cade, working in a small laboratory at a psychiatric hospital in Melbourne, was testing the hypothesis that mania was caused by a toxic substance excreted in urine. He was injecting urea compounds into guinea pigs and needed lithium salts to increase uric acid solubility. When he administered lithium urate to guinea pigs, they became unusually calm. He followed this observation by treating ten patients with chronic manic symptoms with lithium carbonate, and all ten improved — a striking result that he published in the Medical Journal of Australia in 1949.
Cade's discovery was initially slow to gain acceptance, partly because lithium toxicity was poorly understood (lithium carbonate had been used as a salt substitute in cardiac patients in the United States, causing deaths from overdose), and partly because no pharmaceutical company could patent a naturally occurring element. It was Danish psychiatrist Mogens Schou who conducted the randomized controlled trials that established lithium's effectiveness and safety parameters, enabling its eventual approval by the FDA in 1970.
The mechanism by which lithium stabilizes mood remains incompletely understood despite decades of research. The most influential hypothesis — Michael Berridge's inositol depletion theory — proposes that lithium inhibits the enzyme inositol monophosphatase, reducing the recycling of inositol and thereby dampening the activity of inositol-dependent intracellular signaling pathways that are activated by neurotransmitters. A separate and potentially complementary mechanism involves inhibition of glycogen synthase kinase-3 (GSK-3), a multifunctional enzyme involved in circadian rhythm regulation, neuroprotection, neuroplasticity, and neuroinflammation — all processes relevant to bipolar pathophysiology.
Lithium requires blood-level monitoring due to its narrow therapeutic window (therapeutic levels are approximately 0.6-1.2 mEq/L; toxic levels begin above 1.5 mEq/L). Long-term use is associated with renal tubular damage requiring periodic kidney function monitoring, and with hypothyroidism requiring periodic thyroid monitoring. Despite these requirements, lithium has the most robust evidence base of any mood stabilizer for long-term bipolar maintenance and is the only psychiatric medication consistently shown to reduce suicide risk, with patients on lithium maintenance showing approximately 60-80% lower suicide rates than those on alternative mood stabilizers in multiple studies and meta-analyses.
Other Pharmacological Treatments
Valproate (divalproex) is widely used for acute mania and maintenance, and is particularly effective in mixed episodes and rapid cycling. It requires monitoring for hepatotoxicity, is teratogenic (causing neural tube defects and cognitive effects in offspring), and is associated with weight gain and polycystic ovarian syndrome. Lamotrigine has a distinct and clinically important profile: it is effective for the depressive and maintenance phases of bipolar disorder but has limited antimanic efficacy. Its gradual dose titration requirement (to avoid Stevens-Johnson syndrome, a rare but serious skin reaction) means it takes months to reach therapeutic levels, but its tolerability profile makes it particularly useful in bipolar II where depression predominates.
Second-generation antipsychotics, including quetiapine, lurasidone, aripiprazole, and olanzapine-fluoxetine, have FDA approvals for various aspects of bipolar disorder treatment. Quetiapine has the broadest evidence base within the class for bipolar disorder.
Antidepressants are used cautiously. While they can help depressive episodes, their use without a mood stabilizer carries risk of inducing manic switch, mixed states, and accelerated cycling. Current clinical practice guidelines generally recommend against antidepressant monotherapy in bipolar disorder.
Psychosocial Treatments
Interpersonal and Social Rhythm Therapy (IPSRT), developed by Ellen Frank and colleagues at the University of Pittsburgh on the basis of the social zeitgeber theory, is the psychotherapy with the strongest specific evidence base for bipolar disorder. It targets both the social rhythm disruptions that trigger episodes (helping patients regularize sleep schedules, mealtimes, and social routines) and the interpersonal problems — grief, role transitions, and interpersonal disputes — that commonly accompany mood episodes. Randomized controlled trials have found that IPSRT reduces relapse rates when combined with pharmacotherapy.
Cognitive behavioral therapy adapted specifically for bipolar disorder, psychoeducation programs (which teach patients to recognize prodromal symptoms and seek early intervention), and family-focused therapy have all been shown in RCTs to reduce relapse rates and improve functioning as adjuncts to medication.
Suicide Risk and Burden of Illness
Bipolar disorder is associated with an elevated suicide risk more than any other psychiatric diagnosis. Meta-analyses consistently find that individuals with bipolar disorder have suicide rates approximately 20-30 times higher than the general population, and that lifetime rates of suicide attempt in bipolar disorder reach 25-50%. The highest risk is associated with the depressive and mixed phases of the illness, and with rapid cycling.
Untreated bipolar disorder is associated with progressive functional decline over time. Cognitive impairment — deficits in memory, processing speed, and executive function that are present even between episodes — worsens with each successive episode in many patients, consistent with the kindling model. Occupational, financial, and relational consequences accumulate across the course of illness. With effective treatment, however, many patients with bipolar disorder lead full, productive lives.
Bipolar Disorder and Creativity: A Complicated Relationship
The association between mood disorders and creative achievement has fascinated observers since antiquity, from Aristotle's observation that many poets and artists were melancholic to the Romantic idealization of the mad genius. Jamison brought this question into the domain of empirical research with her 1989 study of 47 eminent British writers and artists, published in the British Journal of Psychiatry and expanded in her 1993 book "Touched with Fire: Manic-Depressive Illness and the Artistic Temperament."
Jamison found that 38% of this sample had received treatment for mood disorder — compared to approximately 5% in the general population — with poets showing the highest rates. Subsequent biographical studies have documented high prevalence of bipolar spectrum conditions in many canonical figures in Western art and literature, from Byron and Shelley to Virginia Woolf, Robert Lowell, and Sylvia Plath.
The mechanisms proposed for this association are plausible. Mild hypomanic states share many features with states that facilitate certain kinds of creative output: elevated energy, reduced inhibition, accelerated thought, heightened sensory sensitivity, and increased willingness to take risks including the risk of exploring unconventional ideas. The personality traits associated with bipolar spectrum — openness to experience, emotional intensity, cognitive flexibility — may independently facilitate creative work.
The association, however, must be understood carefully. Full manic episodes are typically not creative states: they involve disorganized thinking, impaired judgment, and behavior that destroys work and relationships. The depressive episodes that comprise most of the illness burden are periods of profound suffering and impaired function. And the vast majority of people with bipolar disorder do not achieve extraordinary creative output — the association reflects a modest statistical relationship between a personality profile associated with the bipolar spectrum and creative ability, not a causal mechanism that makes bipolar disorder productively desirable. Jamison herself, who has spent decades living with both the condition and the myth, has been clear that the benefits of the hypomanic temperament do not offset the suffering of the illness.
Related Articles
For related material on depression, see What Causes Depression?. For the related topic of resilience and recovery, see What Is Resilience?. For a related psychotic disorder with shared genetic architecture, see What Causes Schizophrenia?.
References
- Cade, J. F. J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 36(10), 349–352. https://doi.org/10.1080/j.1440-1614.1999.06241.x
- Coolidge, F. L., Thede, L. L., & Young, S. E. (2002). The heritability of gender identity disorder in a child and adolescent twin sample. Behavior Genetics, 32(4), 251–257. https://doi.org/10.1023/A:1019724712983
- Frank, E., Hlastala, S., Ritenour, A., Houck, P., Tu, X. M., Monk, T. H., Mallinger, A. G., & Kupfer, D. J. (1997). Inducing lifestyle regularity in recovering bipolar disorder patients: Results from the maintenance therapies in bipolar disorder protocol. Biological Psychiatry, 41(12), 1165–1173. https://doi.org/10.1016/S0006-3223(96)00241-7
- Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. The Lancet, 387(10027), 1561–1572. https://doi.org/10.1016/S0140-6736(15)00241-X
- Jamison, K. R. (1993). Touched with Fire: Manic-Depressive Illness and the Artistic Temperament. Free Press.
- Jamison, K. R. (1995). An Unquiet Mind: A Memoir of Moods and Madness. Alfred A. Knopf.
- Merikangas, K. R., Jin, R., He, J. P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., Ladea, M., Medina-Mora, M. E., Ono, Y., Posada-Villa, J., Sagar, R., Wells, J. E., & Zarkov, Z. (2011). Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry, 68(3), 241–251. https://doi.org/10.1001/archgenpsychiatry.2011.12
- Post, R. M. (2007). Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neuroscience and Biobehavioral Reviews, 31(6), 858–873. https://doi.org/10.1016/j.neubiorev.2007.04.003
- Schou, M., Juel-Nielsen, N., Stromgren, E., & Voldby, H. (1954). The treatment of manic psychoses by the administration of lithium salts. Journal of Neurology, Neurosurgery and Psychiatry, 17(4), 250–260. https://doi.org/10.1136/jnnp.17.4.250